Published mark
Emergent BioSolutions Inc.
NYSE: EBS. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:4bbefdeb-32bc-40f6-98b0-22b92d2c2252
- SEC CIK
- 0001367644
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 12, 2026
- Newest evidence
- Mar 20, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Joseph PapaPresident and Chief Executive Officer
- Chair
- Zsolt Harsanyi
- Independent
- Not published8 directors published
- Published claims
- 292 distinct sources
- Evidence records
- 40 pinned
- Source conflicts
- 0None open
Built from 2 distinct sources and 4 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
DIRECTOR APPOINTED
John Fowler, Jr seat on Emergent BioSolutions Inc., effective 2026-01-01.
EffectiveEffective Jan 1, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Executive Vice President, Quality and Ethics and Compliance | Coleen Glessner | Not captured | unknown | Source reportedE2 |
| Senior Vice President, General Counsel and Corporate Secretary | Jessica Perl | Not captured | unknown | Source reportedE2 |
| President and Chief Executive Officer | Joseph Papa | Not captured | unknown | Source reportedE2 |
| Senior Vice President, Products Business | Paul Williams | Not captured | unknown | Source reportedE2 |
| Executive Vice President, Chief Financial Officer | Richard Lindahl | Not captured | unknown | Source reportedE2 |
| Chief Medical Officer, Head of Research and Development | Simon Lowry | Not captured | unknown | Source reportedE2 |
| Senior Vice President, Manufacturing and Bioservices | William Hartzel | Not captured | unknown | Source reportedE2 |
Board of directors
Evidence8 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Donald DeGolyer | Independence not published | 2023 | Compensation Committee, chair | Source reportedE3 |
| John Fowler, Jr | Independence not published | 2026 | None published | Source reportedE3 |
| Kathryn Zoon | Independence not published | 2016 | None published | Source reportedE3 |
| Keith Katkin | Independence not published | 2022 | None published | Source reportedE3 |
| Marvin White | Independence not published | 2020 | Audit and Finance Committee | Source reportedE3 |
| Neal Fowler | Independence not published | 2023 | None published | Source reportedE3 |
| Ronald Richard | Independence not published | 2005 | Nominating and Corporate Governance Committee, chair | Source reportedE3 |
| Sujata Dayal | Independence not published | 2022 | Quality, Compliance, Manufacturing and Risk Management Committee, chair | Source reportedE3 |
| Joseph Papa | Not independent | Not published | President and Chief Executive Officer | Source reportedE2 |
| Zsolt Harsanyi | IndependentChair | Not published | None published | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit and Finance Committee | Not published | Marvin White | financial |
| Compensation Committee | Donald DeGolyer | Donald DeGolyer | Not described in the published record |
| Nominating and Corporate Governance Committee | Ronald Richard | Ronald Richard | Not described in the published record |
| President and Chief Executive Officer | Not published | Joseph Papa | Not described in the published record |
| Quality, Compliance, Manufacturing and Risk Management Committee | Sujata Dayal | Sujata Dayal | regulatory |
Committee RecordAudit and Finance Committee: Chair not stated; Members Marvin White
Committee AppointmentMarvin White: member, Audit and Finance Committee
Committee RecordCompensation Committee: Chair Donald DeGolyer; Members Donald DeGolyer (Chair)
Committee AppointmentDonald DeGolyer: chair, Compensation Committee
Committee RecordNominating and Corporate Governance Committee: Chair Ronald Richard; Members Ronald Richard (Chair)
Committee AppointmentRonald Richard: chair, Nominating and Corporate Governance Committee
Committee RecordQuality, Compliance, Manufacturing and Risk Management Committee: Chair Sujata Dayal; Members Sujata Dayal (Chair)
Committee AppointmentSujata Dayal: chair, Quality, Compliance, Manufacturing and Risk Management Committee
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerJoseph Papa, President and Chief Executive Officer
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingEBS (NYSE)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 12, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameEmergent BioSolutions Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Coleen GlessnerExecutive Vice President, Quality and Ethics and Compliancecompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:15
- Jessica PerlSenior Vice President, General Counsel and Corporate Secretarycompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:16
- Joseph PapaPresident and Chief Executive Officer; Director, President and Chief Executive Officercompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:17, company:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:8
- Paul WilliamsSenior Vice President, Products Businesscompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:18
- Richard LindahlExecutive Vice President, Chief Financial Officercompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:19
- Simon LowryChief Medical Officer, Head of Research and Developmentcompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:20
- William HartzelSenior Vice President, Manufacturing and Bioservicescompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:21
- Donald DeGolyerDirectorcompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:6
- John Fowler, JrDirectorcompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:7
- Kathryn ZoonDirectorcompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:9
- Keith KatkinDirectorcompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:10
- Marvin WhiteDirectorcompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:11
- Neal FowlerDirectorcompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:12
- Ronald RichardDirectorcompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:13
- Sujata DayalDirectorcompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:14
- Zsolt HarsanyiChairman of the Boardcompany:4bbefdeb-32bc-40f6-98b0-22b92d2c2252:leadership_role:5
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 4 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 12, 2026. Cited by 4 Claims.
- E2sec def 14a. Published Mar 20, 2026. Retrieved Sep 6, 2026. Cited by 9 Claims.
- E3sec proxy. Published Mar 20, 2026. Retrieved Sep 2, 2026. Cited by 8 Claims.
- E4governance_people_committees. sec proxy. Cited by 8 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 12, 2026- John Fowler, Jr seat on Emergent BioSolutions Inc., effective 2026-01-01.
- Donald DeGolyer seat on Emergent BioSolutions Inc., effective 2023-01-01.
- Neal Fowler seat on Emergent BioSolutions Inc., effective 2023-01-01.
- Keith Katkin seat on Emergent BioSolutions Inc., effective 2022-01-01.
- Sujata Dayal seat on Emergent BioSolutions Inc., effective 2022-01-01.
- Marvin White seat on Emergent BioSolutions Inc., effective 2020-01-01.
- Kathryn Zoon seat on Emergent BioSolutions Inc., effective 2016-01-01.
- Ronald Richard seat on Emergent BioSolutions Inc., effective 2005-01-01.